Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation

Circulation

Volumn 107, Issue 6, 2003, Pages 831-837

  Oral, Hakan ^a,d   Sivasubramanian, Natarajan ^c   Dyke, David B ^a   Mehta, Rajendra H ^a   Grossman, P Michael ^a   Briesmiester, Kerri ^a   Fay, William P ^a   Pagani, Francis D ^b   Bolling, Steven F ^b   Mann, Douglas L ^c   Starling, Mark R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Cytokines; Hemodynamics; Mitral valve; Remodeling; Surgery

Indexed keywords

BETA ACTIN; CYTOKINE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE; HEART SURGERY; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; MITRAL VALVE REGURGITATION; ORGAN DONOR; PATHOGENESIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIGENS, CD; BIOPSY; CHRONIC DISEASE; CYTOKINES; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; MYOCARDIUM; POSTOPERATIVE PERIOD; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REFERENCE VALUES; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 0037448789     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000049745.38594.6D     Document Type: Article

References (22)

1. Levine B, Kalman J, Mayer L. et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
2. McMurray J, Abdullah I, Dargie HJ. et al. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 1991;66:356-358.
3. Matsumori A, Yamada T, Suzuki H. et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
4. Torre-Amione G, Kapadia S, Benedict C. et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
5. Torre-Amione G, Kapadia S, Lee J. et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
6. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet. 1990;335:294-295.
7. Kubota T, McTiernan CF, Frye CS. et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res. 1997;81:627-635.
8. Bryant D, Becker L, Richardson J. et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation. 1998;97:1375-1381.
9. Bozkurt B, Kribbs SB, Clubb FJ Jr. et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382-1391.
10. Kapadia SR, Oral H, Lee J. et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res. 1997;81:187-195.
11. Kapadia SR, Yakoob K, Nader S. et al. Elevated circulating levels of serum tumor necrosis factor-α in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol. 2000;36:208-212.
12. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503-508.
13. Starling MR, Walsh RA. Accuracy of biplane axial oblique and oblique cineangiographic left ventricular cast volume determinations using a modification of Simpson's rule algorithm. Am Heart J. 1985;110:1219-1225.
14. Starling MR, Dell'Italia LJ, Nusynowitz ML. et al. Equilibrium radionuclide angiographic estimates of absolute left ventricular volumes: importance of attenuation correction. J Nucl Med. 1984;25:14-20.
15. Kapadia S, Lee J, Torre-Amione G. et al. Tumor necrosis factor-a gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 1995;96:1042-1052.
16. Patella V, Marino I, Arbustini E. et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 1998;97:971-978.
17. Torre-Amione G, Kapadia S, Lee J. et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493.
18. Bozkurt B, Torre-Amione G, Warren MS. et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-1047.
19. Spinale FG, Coker ML, Heung LJ. et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944-1949.
20. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
21. Sivasubramanian N, Coker ML, Kurrelmeyer KM. et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826-831.
22. Bradham WS, Moe G, Wendt KA. et al. TNF-α and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Phvsiol. 2002;282:H1288-H1295.